Price$0.81-0.09 (-10.32%)
02:00 PM07:30 PM
News · 26 weeks48-69%
2025-12-142026-06-07
Mix2890d
- SEC Filings13(46%)
- Insider9(32%)
- Other4(14%)
- Earnings2(7%)
Latest news
25 items- PRInspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR ProceduresMIAMI, June 08, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the first patient has been enrolled in the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system ("NPS"), for use with its CGuard Prime 80 cm stent platform, in transcarotid artery revascularization ("TCAR") procedures. The patient was enrolled by Dr. Patrick Muck at Good Samaritan Hospital, part of the TriHealth System in Cincinnati, Ohio. Dr. Muck and Dr. Patrick Geraghty, professor of surgery and radiology, section of vascular surgery at Washington University School
- SECInspireMD Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - InspireMD, Inc. (0001433607) (Filer)
- INSIDERDirector Stuka Paul bought $17,500 worth of shares (20,000 units at $0.88), increasing direct ownership by 3% to 667,871 units (SEC Form 4)4 - InspireMD, Inc. (0001433607) (Issuer)
- SECInspireMD Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - InspireMD, Inc. (0001433607) (Filer)
- INSIDERChief Commercial Officer Gleason Shane Thomas sold $189,594 worth of shares (85,295 units at $2.22), decreasing direct ownership by 7% to 1,053,882 units (SEC Form 4) (for tax liability)4 - InspireMD, Inc. (0001433607) (Issuer)
- INSIDERDirector Stuka Paul bought $17,325 worth of shares (15,000 units at $1.16), increasing direct ownership by 2% to 647,871 units (SEC Form 4)4 - InspireMD, Inc. (0001433607) (Issuer)
- INSIDERCEO and President Slosman Marvin bought $25,200 worth of shares (21,000 units at $1.20), increasing direct ownership by 0.59% to 3,556,658 units (SEC Form 4)4 - InspireMD, Inc. (0001433607) (Issuer)
- INSIDERAmendment: Director Stuka Paul bought $88,026 worth of shares (75,626 units at $1.16), increasing direct ownership by 14% to 632,871 units (SEC Form 4)4/A - InspireMD, Inc. (0001433607) (Issuer)
- INSIDERDirector Stuka Paul bought $88,026 worth of shares (75,626 units at $1.16), increasing direct ownership by 14% to 632,871 units (SEC Form 4)4 - InspireMD, Inc. (0001433607) (Issuer)
- INSIDERDirector Ward Scott R. bought $102,638 worth of shares (89,250 units at $1.15), increasing direct ownership by 60% to 237,096 units (SEC Form 4)4 - InspireMD, Inc. (0001433607) (Issuer)
- INSIDERDirector Stuka Paul bought $9,034 worth of shares (7,895 units at $1.14), increasing direct ownership by 2% to 531,599 units (SEC Form 4)4 - InspireMD, Inc. (0001433607) (Issuer)
- INSIDERDirector Roubin Gary S bought $106,200 worth of shares (90,000 units at $1.18), increasing direct ownership by 12% to 834,478 units (SEC Form 4)4 - InspireMD, Inc. (0001433607) (Issuer)
- SECSEC Form 10-Q filed by InspireMD Inc.10-Q - InspireMD, Inc. (0001433607) (Filer)
- PRInspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare ConferenceMIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming Bank of America Securities 2026 Global Healthcare Conference on Wednesday, May 13th at 4:20 pm Pacific Time (PT). A live audio webcast and an archive of the recording will be available through the Investors page of InspireMD's corporate website at https://investors.inspiremd.com. About InspireMD, Inc.InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acu
- SECInspireMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - InspireMD, Inc. (0001433607) (Filer)
- SECInspireMD Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - InspireMD, Inc. (0001433607) (Filer)
- PRInspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection SystemMIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the U.S. Food and Drug Administration ("FDA") has approved the company's Investigational Device Exemption ("IDE") Application to initiate the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system ("NPS"), including next generation enhancements from our prior IDE approval for use with its CGuard Prime 80 cm stent platform, in transcarotid artery revascularization ("TCAR") procedures. Patrick Geraghty, M.D., professor of surgery and radiology, section of vascular surgery
- PRInspireMD to Announce First Quarter 2026 Financial ResultsMIAMI, April 27, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its first quarter financial results on Monday, May 4, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin. A live audio webcast an
- SECSEC Form DEFA14A filed by InspireMD Inc.DEFA14A - InspireMD, Inc. (0001433607) (Filer)
- SECSEC Form DEFA14A filed by InspireMD Inc.DEFA14A - InspireMD, Inc. (0001433607) (Filer)
- SECSEC Form DEF 14A filed by InspireMD Inc.DEF 14A - InspireMD, Inc. (0001433607) (Filer)
- SECSEC Form PRE 14A filed by InspireMD Inc.PRE 14A - InspireMD, Inc. (0001433607) (Filer)
- SECInspireMD Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - InspireMD, Inc. (0001433607) (Filer)
- SECSEC Form 424B5 filed by InspireMD Inc.424B5 - InspireMD, Inc. (0001433607) (Filer)
- PRInspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare ConferenceMIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14th at 12:45 pm Eastern Time (ET). A live audio webcast and an archive of the recording will be available through the Investors page of InspireMD's corporate website at https://investors.inspiremd.com. About InspireMD, Inc.InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free lon
NSPR FAQ
6 questionsWhat does InspireMD Inc. do?
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that...Where does NSPR stock trade?
InspireMD Inc. (NSPR) is listed on AMEX.What sector and industry is NSPR in?
InspireMD Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about NSPR?
InspireMD Inc. has had 1 recent analyst action on file. The most recent action was from Maxim Group: Buy with a $600.00 price target on 2026-02-02. Recent price targets cluster around $600.00.What companies are similar to NSPR?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare NSPR side-by-side with any of them on Quantisnow.How can I track NSPR on Quantisnow?
Quantisnow aggregates InspireMD Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NSPR to receive live email and push alerts on every new disclosure.